spacer
home > ebr > summer 2003 > the potential of zinc ions for prophylaxis and treatment of severe acute respiratory syndrome (sars)
PUBLICATIONS
European Biopharmaceutical Review

The Potential of Zinc Ions for Prophylaxis and Treatment of Severe Acute Respiratory Syndrome (SARS)

The discovery that SARS is caused by a coronavirus, related to a group of viruses causing the common cold, may be significant in relation to evidence that zinc ions provide a natural protective mechanism against viruses - especially those such as rhinoviruses that cause respiratory tract infections. The effect of zinc is multi-factorial and is based on direct antiviral effects of zinc ions; amplification and maintenance of immunity; augmentation of interferon activity; and a natural defence mechanism at the cell membrane level. It is suggested that the SARS virus be tested for sensitivity to zinc ions. Because zinc deficiency is a worldwide public health problem, it is worth considering zinc supplementation as a prophylactic and therapeutic measure in the SARS outbreak. In order to maximise zinc absorption and possible local zinc ion action in the buccal cavity, it is suggested that the supplementation should be in the form of 9 to 15mg strength zinc lozenges designed to release divalent zinc ions.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr George Rowland, Chairman and Co-Founder of ZinCare International Ltd

Dr George Rowland is Chairman and Co-Founder of ZinCare International Ltd UK, and Immunotech cc South Africa; companies specialising in the health benefits of zinc, in association with Zeon Healthcare Ltd. Dr Rowland received his PhD in Biochemistry from University College, London in 1961.

After 12 years in academic research and one year at the Walter & Elisa Hall Institute, Melbourne, he moved into research in the UK pharmaceutical industry at GD Searle and later as Head of Immunology at Eli Lilly. In 1985 he moved to South Africa to become a Founding Director of Bioclones, South Africa's first biotechnology company, before leaving in 2000 to concentrate on his present activities.
spacer
Dr George Rowland
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Entry now open for the PPMA Group Industry Awards 2019

The 2019 PPMA Group Industry Awards will be held at the National Conference Centre (NEC), Birmingham, on the evening of the first day of the PPMA Total Show 2019 – Tuesday, 1 October 2019. 
More info >>

White Papers

Orthogonal Approaches for the Analysis of Protein Sequence

Ludger Ltd

One of the most important classes of biopharmaceuticals is monoclonal antibodies. They are expressed from living cells, and are consequently subject to complex biochemical pathways. Not all of these routes are fully understood, and many are sensitive to the subtlest of environmental changes. Changes such as these can affect the final biopharmaceutical sequence, structure and post-translational modifications, not to mention any changes that may occur during further purification. This often means that the final product from one batch may be different from the last in another batch. Each batch is a complicated mix of similar molecules, and analysis of the degree of batch-to-batch variation is therefore very important to the establishment of the drug's safety for medicinal use and patient administration.
More info >>

 
Industry Events

BioPharm America™ 2019—12th Annual International Partnering Conference

11-12 September 2019, Boston Convention and Exhibition Center (BCEC), Boston, MA 02210 USA

BioPharm America™ is a unique partnering event that forms the nexus of discovery and realization. Startup companies, established biotech and entrepreneurs from academia attend in search of finance, pharma and development partners. The event format highlights innovation and promotes new business relationships by bringing dealmakers from the life science ecosystem together to engage and de-risk the enormous task of drug development. Life science executives from around the world gather to identify, meet and to enter into strategic relationships facilitated by partneringONE®, the world’s leading web-based partnering system. BioPharm America is the only event in North America based on the same reputable formula as EBD Group’s acclaimed European events BIO-Europe® and BIO-Europe Spring®. BioPharm America annually attracts 800+ delegates from over 500 companies who participated in 2,300+ scheduled one-to-one meetings. BioPharm America is now part of Biotech Week Boston, and together they draw a total of over 4,500 life science leaders, scientists and innovators.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement